To explore how CXCR2 inhibition of myeloid cell chemotaxis impacted mCRPC biology, we carried out capture-based RNA profiling (HTG EdgeSeq) from paired pre- and on-treatment mCRPC biopsies (seven pairs of biopsies had sufficient tumour content) from the patients with reduced intratumour CD11b+HLA-DRloCD15+CD14− myeloid cell density after treatment. This evidence concerns the gene CXCR2 and neoplasm.